- Home
- SENEB vs GHRS Comparison
SENEB vs GHRS Comparison
Compare SENEB & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SENEB | GHRS |
|---|---|---|
| Founded | 1949 | 2018 |
| Country | United States | Ireland |
| Employees | 6895 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 880.5M | 947.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SENEB | GHRS |
|---|---|---|
| Price | $137.55 | $20.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $41.38 |
| AVG Volume (30 Days) | 473.0 | ★ 235.7K |
| Earning Date | 06-11-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $90.19 | $9.52 |
| 52 Week High | $164.98 | $24.66 |
Technical Indicators
Market Signals| Indicator | SENEB | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 53.94 | 65.41 |
| Support Level | $131.45 | $12.54 |
| Resistance Level | $164.98 | $24.66 |
| Average True Range (ATR) | 0.31 | 1.62 |
| MACD | -1.73 | 0.16 |
| Stochastic Oscillator | 17.98 | 50.55 |
Price Performance
Historical ComparisonAbout SENEB Seneca Foods Corp. Class B
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.